Volume 88 Issue 6 | pp. 30-33
Issue Date: February 8, 2010

Antibiotics Yo-Yo

Companies score big deals but still struggle with regulatory authorities
Department: Business | Collection: Special Issue
Keywords: antibiotics, AstraZeneca, Novexel, Novartis, Pfizer, gram-negative bacteria, gram-positive bacteria, MRSA

It’s been a turbulent few years for companies developing antibiotics. Several late-stage drug candidates have suffered setbacks, and companies claim the regulatory environment has become confusing at best. But the Food & Drug Administration is beginning to offer more clarity on data it needs to approve new antibiotics. And as more development programs reach late-stage trials, biotech firms with promising drugs are finding partners ready to pay big bucks for them.

Since October 2009,

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society